The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
PURPOSE: The effects of metformin on the prognosis of kidney cancer patients with diabetes are in controversial. The present study is conducted to classify the association of metformin use with the survival of patients with kidney cancer. METHODS: Electronic databases, namely PubMed and Web of Science, were used to search the eligible studies up to December, 2016. Pooled hazard ratio (HR) and its corresponding 95% confidence interval (95% CI) were calculated. It was considered as statistically significant when P value was <0.05. RESULTS: Eight cohorts were eligible for the present meta-analysis, including 254,329 kidney cancer patients. The combined HR suggested that the use of metformin could improve the overall survival (OS) (HR 0.643, 95% CI 0.520-0.795, P < 0.001) and cancer-specific survival (CSS) (HR 0.618, 95% CI 0.446-0.858, P = 0.004) in kidney cancer patients. In subgroup analysis, positive associations were found between metformin use and OS/CSS of localized renal cell carcinoma patients (OS: HR 0.634, 95% CI 0.440-0.913, P = 0.014; CSS: HR 0.476, 95% CI 0.295-0.768, P = 0.002). Moreover, we also found that the use of metformin could reduce the risk of death in kidney cancer patients (HR 0.711, 95% CI 0.562-0.899, P = 0.004). CONCLUSION: Our findings suggest that the use of metformin is in favor of the prognosis of patients with kidney cancers. Further investigations are needed to evaluate the prognostic value of metformin on kidney cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There are data to support a modest reduction of obesity-related cancers with weight loss (HR, 0.84; 95% CI, 0.68–1.04) in persons with DM”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1780]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“but without a significant impact on total cancer incidence or mortality.1780”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1780]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Epidemiology and risk factors for kidney cancer
Chow, W.-H., Dong, L. M., & Devesa, S. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.46 · Cited by 1,384
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · cited 1×
“Metformin, a biguanide, is widely used for the therapy of diabetes with sulphonylureas [10].”
BackgroundUse of metformin and risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.027 · Cited by 69
The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies
Chen, L., Li, H., Gu, L., Ma, X., Li, X., Gao, Y., Zhang, Y., Shen, D., Fan, Y., Wang, B., et al. (2015) · Medicine · doi:10.1097/md.0000000000001055 · Cited by 65
Mayer, M., Klotz, L. H., & Venkateswaran, V. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.069 · Cited by 43
Hakimi, A. A., Chen, L., Kim, P. H., Sjoberg, D. D., Glickman, L., Walker, M. R., & Russo, P. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.1447 · Cited by 37
Psutka, S. P., Boorjian, S. A., Lohse, C. M., Stewart, S. B., Tollefson, M. K., Cheville, J. C., Leibovich, B. C., & Thompson, R. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.07.008 · Cited by 36
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
Hamieh, L., McKay, R. R., Lin, X., Moreira, R. B., Simantov, R., & Choueiri, T. K. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.06.017 · Cited by 34
Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis
Nayan, M., Finelli, A., Jewett, M. A. S., Juurlink, D. N., Austin, P. C., Kulkarni, G. S., & Hamilton, R. J. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.06.008 · Cited by 30
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 260
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets
Tan, S. K., Hougen, H. Y., Merchan, J. R., Gonzalgo, M. L., & Welford, S. M. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00654-6 · Cited by 179
Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells
Saini, N., & Yang, X. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx106 · Cited by 174
Metadata
- Authors
- Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y.
- Affiliations
- Chongqing Medical University (CN)
- Venue
- International Urology and Nephrology
- Published
- 2017-03-07
- Volume
- 49
- Issue
- 6
- Pages
- 975-981
- ISSN
- 0301-1623 (ISSN-L)
- 1573-2584
- PMC
- PMC5443884
- OpenAlex
- W2593712675
- Cited by
- 38
- References
- 20
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 3
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Urology and Nephrology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, kidney cancer, renal cell carcinoma, diabetes mellitus, overall survival, cancer-specific survival, prognosis, drug repurposing
- MeSH terms
- Carcinoma, Renal Cell, Diabetes Mellitus, Humans, Hypoglycemic Agents, Kidney Neoplasms, Metformin, Survival Rate, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. https://app.cochat.ai/papers/10.1007/s11255-017-1548-4
- The paper
- Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y. (2017). The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-017-1548-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.